Novartis eyes a new market with its buyout of a small digital therapeutics player
Novartis has scooped up a digital therapeutics player working on a new treatment for lazy eye.
The company is Phoenix-based Amblyotech, which has been pursuing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.